Intravenous gamma-globulin inhibits binding of anti-GM1 to its target antigen.
In this study, we preincubated the sera of 3 patients with neuropathies associated with elevated titers of IgM anti-GM1 antibodies, with increasing concentrations of intravenous Ig (IVIg) and assayed the inhibitory effect of this mixture on antibody binding to immobilized GM1 by an enzyme-linked immunosorbent assay. Pharmacologic concentrations of IVIg, ranging from 0.1 microgram/ml to 100 mg/ml, inhibited anti-GM1 binding to its target antigen from 26 +/- 3 to 71 +/- 7%, respectively, in a dose-dependent manner. A similar inhibition of binding was also observed with IVIg F(ab')2 fragments. These findings provide a possible mechanism for the clinical efficacy of IVIg in motor neuropathies.
Malik
U
U
Department of Oncology, Montefiore Hospital, Albert Einstein College of Medicine, Bronx, NY 10467, USA.
Oleksowicz
L
L
Latov
N
N
Cardo
L J
LJ
D004305:Dose-Response Relationship, Drug; D004797:Enzyme-Linked Immunosorbent Assay; D005677:G(M1) Ganglioside / Q000276:immunology / Q000378:metabolism*; D006801:Humans; D007075:Immunoglobulin M / Q000097:blood / Q000378:metabolism*; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage / Q000494:pharmacology*; D016472:Motor Neuron Disease / Q000276:immunology* / Q000628:therapy*; D011485:Protein Binding / Q000187:drug effects; D005719:gamma-Globulins / Q000008:administration & dosage / Q000494:pharmacology*
D007075:Immunoglobulin M; D016756:Immunoglobulins, Intravenous; D005719:gamma-Globulins; D005677:G(M1) Ganglioside